MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
发明人:
TERZIC, ANDRE,BEHFAR, ATTA
申请号：
NZ60092009
公开号：
NZ600920A
申请日:
2009.05.20
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
600920 Disclosed is the use of a composition comprising TGFp-1, BMP4, a-thrombin, Cardiotrophin, and Cardiogenol C in manufacture of a medicament for the treatment of ischemic cardiomyopathy, myocardial infarction, or heart failure. Further disclosed is the use of a population of cells guided towards cardiopoiesis in the manufacture of a medicament for treatment of ischemic cardiomyopathy, myocardial infarction, or heart failure in a mammal, wherein the population of cells guided towards cardiopoiesis are obtained by a method comprising (i) culturing initial cells in the presence of a composition comprising TGF?-1, BMP4, ?-thrombin, Cardiotrophin, and Cardiogenol C and (ii) determining that a sample of cells from a population of cells guided towards cardiopoiesis comprises cells that express an elevated level of at least one of the mRNA selected from the group consisting of MEF2c mRNA, MESP-1 mRNA, Tbx-5 mRNA, GATA4 mRNA , Flk-1 mRNA, GATA6 mRNA, Fog-1 mRNA, and combinations thereof, and/or have at least one polypeptide selected from the group consisting of Nkx2.5 polypeptides, MEF2C polypeptides, Tbx-5 polypeptides, MESP-1 polypeptides, GATA-4 polypeptides, FOG-2 polypeptides, and combinations thereof, wherein said polypeptide is associated with the nuclei of said cells.
